Aimei Health Technology Co., Ltd. Calls Shareholder Meeting

TL;DR

Aimei Health Tech (AHCT) calling shareholder meeting Jan 21, 2025. Details to follow.

AI Summary

Aimei Health Technology Co., Ltd. filed a Definitive Proxy Statement (DEF 14A) on January 21, 2025. The filing concerns an upcoming Extraordinary General Meeting of Shareholders. The company's principal executive offices are located at 10 East 53rd Street, Suite 3001, New York, NY 10022.

Why It Matters

This filing signals that Aimei Health Technology Co., Ltd. is convening a shareholder meeting to discuss important company matters, which could impact future strategic decisions and shareholder value.

Risk Assessment

Risk Level: low — This is a routine proxy filing announcing a shareholder meeting, not indicating immediate financial distress or significant operational changes.

Key Players & Entities

• Aimei Health Technology Co., Ltd. (company) — Registrant
• January 21, 2025 (date) — Filing Date
• 10 East 53rd Street, Suite 3001, New York, NY 10022 (location) — Company Address

FAQ

Key Financial Figures

• $0.033 — its initial business combination, from $0.033 per Public Share (as defined below) (fo
• $60,000 — onthly extension) to an amount equal to $60,000 for all outstanding Public Shares (for
• $10.65 — net of taxes payable, was approximately $10.65 per Public Share as of December 23, 202
• $10.60 — h’s shares on the Record Date was $10.60. Aimei Health cannot assure shareholder

Filing Documents

• formdef14a.htm (DEF 14A) — 382KB
• proxy_001.jpg (GRAPHIC) — 1738KB
• proxy_002.jpg (GRAPHIC) — 1500KB
• 0001493152-25-002879.txt ( ) — 4841KB

From the Filing

DEF 14A 1 formdef14a.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant   Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to Section 240.14a-12 AIMEI HEALTH TECHNOLOGY CO., LTD (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. AIMEI HEALTH TECHNOLOGY CO., LTD 10 East 53rd Street, Suite 3001 New York, NY 10022 +86 13758131392 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 4, 2025 TO THE SHAREHOLDERS OF AIMEI HEALTH TECHNOLOGY CO., LTD: You are cordially invited to attend the extraordinary general meeting of shareholders of Aimei Health Technology Co., Ltd (“ Aimei Health ,” “ Company ,” “ we ,” “ us ” or “ our ”) to be held on February 4, 2025 in person in the offices of the Company’s counsel, Hunter Taubman Fischer & Li LLC, at 950 Third Avenue, 19th Floor, New York, NY 10022 and virtually at 10:00 a.m. Eastern Time, or at such other time, on such other date and at such other place at which the meeting may be adjourned (the “ Extraordinary General Meeting ”). If you plan on attending the Extraordinary General Meeting in person, please email xiejunheng@aimeihealth.com at least one day prior to the Extraordinary General Meeting. If you plan on attending the Extraordinary General Meeting online, you will be able to vote and submit your questions during the Extraordinary General Meeting by visiting https://www.virtualshareholdermeeting.com/AFJKU2025 shortly prior to the start of the meeting and entering the 16-digit control number found on the proxy card or voting instruction form. A person participating in the Extraordinary General Meeting in the virtual meeting format is deemed to be present in person at the meeting. The purpose of the Extraordinary General Meeting will be to consider and vote on the following proposals: 1. Proposal 1 – To approve, by special resolution, an amendment to Article 35.2 of the Amended and Restated Articles of Association of the Company currently in effect (the “ Articles ”) to insert the words “ , or, if such trust agreement has been amended, in that trust agreement, as amended from time to time, in accordance with its terms ” after the words “ and referred to in the Registration Statement ” in that Article (the “ Article Amendment Proposal ”); 2. Proposal 2 – To approve an amendment to the Investment Management Trust Agreement dated December 1, 2023 (the “ Trust Agreement ”), entered into by and between Continental Stock Transfer & Trust Company, as trustee (the “ Trustee ”) and the Company governing the trust account established in connection with the Company’s initial public offering (“ IPO ”), to amend the amount of funds to be deposited by our sponsor, Aimei Investment Ltd (the “ Sponsor ”) into the trust account in connection with extending the timeframe within which the Company must consummate its initial business combination, from $0.033 per Public Share (as defined below) (for each monthly extension) to an amount equal to $60,000 for all outstanding Public Shares (for each monthly extension) (the “ Trust Agreement Amendment Proposal ”); 3. Proposal 3 – To approve, by ordinary resolution, the engagement of MaloneBailey, LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2023 and approve the engagement of MaloneBailey, LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2024 (the “ Auditor Appointment Proposal ”); and 4. Proposal 4 – To approve, by ordinary resolution, to direct the chairman of the Extraordinary General Meeting to adjourn the Extraordinary General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes for, or otherwise in connection with, the approval of the foregoing proposals (the “ Adjournment Proposal ”). Each of the Article Amendment Proposal, the Trust Agreement Amendment Proposal, the Auditor Appointment Proposal, and the Adjournment Proposal (together the “ Proposals ”) is more fully describ

View Full Filing

View this DEF 14A filing on SEC EDGAR